Welcome to our dedicated page for Bowen Acquisition SEC filings (Ticker: BOWN), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Bowen Acquisition Corp (BOWN) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as a special purpose acquisition company (SPAC) and shell company in the financial services sector. Bowen Acquisition Corp files reports with the U.S. Securities and Exchange Commission (SEC) as a Nasdaq-listed issuer, and these documents explain its SPAC structure, trust arrangements, shareholder approvals, and proposed business combination.
Current reports on Form 8-K are particularly important for BOWN. They include details of material events such as the execution of the merger agreement with Shenzhen Qianzhi BioTechnology Co. Ltd. and its parent entity, shareholder meetings to extend the deadline for completing a business combination, and notices from Nasdaq regarding non-compliance with continued listing standards, trading halts, and delisting determinations. These filings outline the conditions imposed by Nasdaq panels and the company’s responses, including appeals and requests for review.
Periodic reports such as Forms 10-Q and related notifications of late filing (Form 12b-25) provide information on Bowen Acquisition Corp’s reporting status and operational context as a SPAC. In its Form 12b-25, the company explains the reasons for delays in filing a quarterly report, including the absence of full-time accounting and administrative staff and its ongoing efforts to complete its initial business combination.
On Stock Titan, AI-powered tools can help interpret BOWN’s filings by highlighting key sections related to its proposed merger with Shenzhen Qianzhi BioTechnology Co. Ltd., extensions of its business combination deadline, trust account disclosures, and Nasdaq listing status. Users can review real-time updates from EDGAR, track new Forms 8-K and 10-Q as they are filed, and examine any available insider-related information such as changes in share structure or rights. This context allows investors and researchers to understand how Bowen Acquisition Corp is progressing toward a business combination and how regulatory and listing developments may affect its securities.
Bowen Acquisition Corp reported that its shareholders approved a charter amendment giving the board of directors authority to extend the deadline to complete an initial business combination. The change was adopted at an extraordinary general meeting held on December 12, 2025.
A total of 2,616,701 ordinary shares were represented at the meeting. The proposal passed with 2,612,224 votes in favor and 4,477 against, with no abstentions or broker non-votes. The company stated that it is continuing to attempt to satisfy the remaining conditions to close its proposed business combination with Shenzhen Qianzhi BioTechnology Co. Ltd.
Bowen Acquisition Corp. (BOWN) filed a Form 12b-25 (NT 10-Q) to notify a delayed filing of its Quarterly Report for the period ended September 30, 2025. The company states it cannot file within the prescribed time without unreasonable effort and expense.
Bowen cites the need for additional time to compile and process required information because it does not have full-time accounting and administrative staff. It also notes it has been in the process of seeking to consummate its initial business combination, which adds to the timing constraints.
Bowen Acquisition Corp (BOWN) calls a shareholder vote to extend its SPAC deadline. The extraordinary general meeting is set for 10:00 a.m. ET on December 12, 2025, to approve an amendment allowing up to six one‑month extensions, moving the current termination date from December 14, 2025 to as late as June 14, 2026. A separate proposal would permit adjournment if more time is needed to effect the extension.
Public shareholders may elect to redeem their shares for cash from the trust by submitting shares to the transfer agent by 5:00 p.m. ET on December 10, 2025. The company notes shareholders had already approved its business combination with Shenzhen Qianzhi BioTechnology in January 2025, but closing remains pending. If the extension fails and no deal closes by December 14, 2025, Bowen will redeem public shares and liquidate per its charter.
As of the record date November 12, 2025, 2,994,371 ordinary shares were outstanding, including 727,871 public shares. Sponsors and insiders hold 2,066,782 shares (approximately 69%) and intend to vote in favor.
Bowen Acquisition Corp. (BOWN) reported a Nasdaq delisting decision. Nasdaq notified the company on
After an appeal and hearing on
FAQ
What is the current stock price of Bowen Acquisition (BOWN)?
What is the market cap of Bowen Acquisition (BOWN)?
